ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pirfenidone

Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.

Drug pagePirfenidone: every studyMany companies study it; this page follows only the 29 they lead. All 102 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 4, 201529 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only120 open or runningphase 4since Nov 4, 2015Mar 24, 2004none ahead
GNI Groupits history only72 open or runningphase 3since Feb 26, 2019Nov 18, 2014Dec 30, 2026phase 3 · NCT07388680
PureTechits history only52 open or runningphase 3since Dec 8, 2025Jan 21, 2020Nov 2029phase 3 · NCT07284602
Overseas Pharmaceuticals30 open or runningphase 1since Aug 22, 2024Aug 22, 2024none ahead
Beijing Kawin Technology Share-Holdingits history only10 open or runningphase 2since Dec 30, 2011Dec 30, 2011none ahead
Grupo Medifarma, S. A. de C. V.its history only10 open or runningphase 3since Jul 6, 2015Jul 6, 2015none ahead

Also a collaborator on its studies: Clinipace Worldwide, Novotech (Australia) Pty, Shanghai Genomics and GNI-EPS Pharmaceuticals, Inc. (GNI Group).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 22, 2024First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT06569381 · 18 enrolled · China
  2. Sep 6, 20242 phase 1 studies in Idiopathic Pulmonary FibrosisNCT06589921, NCT06588517

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Overseas Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06589921Idiopathic Pulmonary Fibrosis · China1CompletedSep 5, 202324
NCT06588517Idiopathic Pulmonary Fibrosis · China1CompletedApr 19, 202412
NCT06569381Idiopathic Pulmonary Fibrosis · China1CompletedOct 1, 202418

How it is read

Names in the registry

  • “Pirfenidone”, 26 entries
  • “Pirfenidone Modified-Release Tablets”, 4 entries
  • “Deupirfenidone”, 3 entries
  • “pirfenidone capsule”, 2 entries
  • “pirfenidone”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.